ENOV Stock Overview
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ENOV from our risk checks.
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.10 |
| 52 Week High | US$66.14 |
| 52 Week Low | US$43.04 |
| Beta | 2.07 |
| 1 Month Change | -8.59% |
| 3 Month Change | -7.86% |
| 1 Year Change | -4.79% |
| 3 Year Change | -59.28% |
| 5 Year Change | -38.26% |
| Change since IPO | -12.54% |
Recent News & Updates
Recent updates
Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks
Apr 22
Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Feb 12Is Enovis (NYSE:ENOV) Using Too Much Debt?
Jan 14Investors Holding Back On Enovis Corporation (NYSE:ENOV)
Dec 18Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)
Nov 05Enovis Making Good Choices, But Not Seeing The Rewards
Sep 27Is Enovis (NYSE:ENOV) A Risky Investment?
Sep 22Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
Aug 03Enovis Corporation: Things Are Looking Good As Guidance Is Raised
Jul 18We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt
Jun 20Enovis Corporation Q4 2022 Earnings Preview
Feb 22Is Enovis (NYSE:ENOV) A Risky Investment?
Feb 22Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?
Jan 25Enovis Corporation reports Q3 earnings beat; updates FY22 guidance
Nov 02Is Enovis (NYSE:ENOV) A Risky Investment?
Oct 19Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?
Sep 14Enovis launches augmented reality system ARVIS for use in hip, knee surgery
Jul 19Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly
Jul 05Enovis announces CFO transition
Jun 30Enovis: Medtech Leftover Of Colfax With Some To Prove
May 23As The Colfax Chapter Ends, Both ESAB And Enovis Have Something To Prove
Apr 05Is Colfax (NYSE:CFX) Using Too Much Debt?
Feb 20With EPS Growth And More, Colfax (NYSE:CFX) Is Interesting
Jan 05Colfax - Thoughts Ahead Of The Spin-Off
Jan 04Colfax Corporation (NYSE:CFX) Shares Could Be 32% Below Their Intrinsic Value Estimate
Dec 21Is Colfax (NYSE:CFX) Using Too Much Debt?
Nov 21Do Colfax's (NYSE:CFX) Earnings Warrant Your Attention?
Sep 30Is There An Opportunity With Colfax Corporation's (NYSE:CFX) 29% Undervaluation?
Sep 13Colfax: Setup Turns Compelling Heading Into The Upcoming Separation Event
Aug 15Shareholder Returns
| ENOV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.3% | 1.6% | 1.0% |
| 1Y | -4.8% | -1.4% | 21.9% |
Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: ENOV underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ENOV volatility | |
|---|---|
| ENOV Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENOV has not had significant price volatility in the past 3 months.
Volatility Over Time: ENOV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
| ENOV fundamental statistics | |
|---|---|
| Market cap | US$3.02b |
| Earnings (TTM) | -US$54.37m |
| Revenue (TTM) | US$1.71b |
1.8x
P/S Ratio-55.6x
P/E RatioIs ENOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENOV income statement (TTM) | |
|---|---|
| Revenue | US$1.71b |
| Cost of Revenue | US$713.67m |
| Gross Profit | US$993.53m |
| Other Expenses | US$1.05b |
| Earnings | -US$54.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 58.20% |
| Net Profit Margin | -3.18% |
| Debt/Equity Ratio | 13.6% |
How did ENOV perform over the long term?
See historical performance and comparison